Menu
Search
|

Menu

Close
X

Aralez Pharmaceuticals Inc ARLZ.OQ (NASDAQ Stock Exchange Global Select Market)

1.62 USD
-0.00 (-0.31%)
As of Feb 16
chart
Previous Close 1.62
Open 1.60
Volume 49,577
3m Avg Volume 105,431
Today’s High 1.67
Today’s Low 1.57
52 Week High 4.65
52 Week Low 0.95
Shares Outstanding (mil) 66.89
Market Capitalization (mil) 108.02
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY17
78
FY16
54
FY15
21
EPS (USD)
FY17
-1.200
FY16
-1.710
FY15
-1.156
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
1.10
8.57
Price to Book (MRQ)
vs sector
1.83
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
464.34
15.12
LT Debt to Equity (MRQ)
vs sector
464.34
11.85
Return on Investment (TTM)
vs sector
-33.44
13.54
Return on Equity (TTM)
vs sector
-105.46
14.80

EXECUTIVE LEADERSHIP

Arthur Kirsch
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Andrew Koven
President, Chief Business Officer, Since 2016
Salary: --
Bonus: --
Adrian Adams
Chief Executive Officer, Director, Since 2016
Salary: --
Bonus: --
Michael Kaseta
Head of Finance and Interim Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Since 2017
Salary: --
Bonus: --
Jennifer Armstrong
Executive Vice President - Human Resources and Administration, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

7100 West Credit Ave Suite 101
MISSISSAUGA   ON   L5N 0E4

Phone: +1905.8761118
Site: aralez.com/

Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).

SPONSORED STORIES